UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Analysis of cancer metabolism with high-throughput technologies

BMC bioinformatics, 2011-10, Vol.12 Suppl 10 (S10), p.S8-S8, Article S8

2011

Volltextzugriff (PDF)

Promoter prediction in E. coli based on SIDD profiles and Artificial Neural Networks

BMC bioinformatics, 2010-10, Vol.11 Suppl 6 (S6), p.S17-S17, Article S17

2010

Volltextzugriff (PDF)

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Cancer research (Chicago, Ill.), 2015-06, Vol.75 (12), p.2489-2500

2015

Volltextzugriff (PDF)

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON

Cancer discovery, 2023-01, Vol.13 (1), p.98-113

2023

Volltextzugriff (PDF)

Promoter prediction in E. coli based on SIDD profiles and Artificial Neural Networks

BMC bioinformatics, 2010-10, Vol.11 (Suppl 6), p.S17-S17

2010

Volltextzugriff (PDF)

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

Nucleic acids research, 2016-06, Vol.44 (11), p.e108-e108

2016

Volltextzugriff (PDF)

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.841-849

2018

Volltextzugriff (PDF)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers

Nature communications, 2021-03, Vol.12 (1), p.1780-1780, Article 1780

2021

Volltextzugriff (PDF)

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

Nature medicine, 2015-06, Vol.21 (6), p.560-562

2015

Volltextzugriff (PDF)

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nature communications, 2023-02, Vol.14 (1), p.1070-1070, Article 1070

2023

Volltextzugriff (PDF)

Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2020-01, Vol.15 (1), p.50-61

2020

Volltextzugriff (PDF)

Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA

Journal of thoracic oncology, 2020-01, Vol.15 (1), p.138-143

2020

Volltextzugriff (PDF)

Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Nature communications, 2019-11, Vol.10 (1), p.5167-19, Article 5167

2019

Volltextzugriff (PDF)

Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models

Therapeutic advances in medical oncology, 2022-02, Vol.14, p.17588359221079125-17588359221079125

2022

Volltextzugriff (PDF)

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nature communications, 2023-06, Vol.14 (1), p.3179-3179, Article 3179

2023

Volltextzugriff (PDF)

Abstract CT024: Acquired resistance in patients with EGFRm NSCLC following treatment with osimertinib plus savolitinib in the Ph1b TATTON study Parts B and D

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT024-CT024

2021

Volltextzugriff (PDF)

Abstract 5268: Seq2C: from sequence to copy number for cancer samples

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.5268-5268

2016

Volltextzugriff (PDF)

Abstract CT127: Tumor response and MET-detection methods exploratory biomarker analysis of Part B of the Ph 1b TATTON study

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT127-CT127

2021

Volltextzugriff (PDF)

Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer

Clinical pharmacology and therapeutics, 2024-02, Vol.115 (2), p.349-360

2024

Volltextzugriff (PDF)

Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)

Journal of clinical oncology, 2023-05, Vol.41 (14), p.2493-2502

2023

Volltextzugriff (PDF)

Abstract CT024: Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT024-CT024

2020

Volltextzugriff (PDF)

Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8005-8005

2024

Volltextzugriff (PDF)

Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations

Clinical cancer research, 2024-05, p.OF1-OF12

2024

Volltextzugriff (PDF)

A new Ornithoctona (Diptera: Hippoboscidae) species from Baikal State Nature Reserve (Russia)

Nature Conservation Research: Заповедная наука, 2023-01, Vol.8 (3)

2023

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(57)
Dissertationen
(1)

Sprache

Englisch
(53)
Japanisch
(14)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Analysis of cancer metabolism with high-throughput technologies

Promoter prediction in E. coli based on SIDD profiles and Artificial Neural Networks

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON

Promoter prediction in E. coli based on SIDD profiles and Artificial Neural Networks

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer

Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer

Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA

Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Abstract CT024: Acquired resistance in patients with EGFRm NSCLC following treatment with osimertinib plus savolitinib in the Ph1b TATTON study Parts B and D

Abstract 5268: Seq2C: from sequence to copy number for cancer samples

Abstract CT127: Tumor response and MET-detection methods exploratory biomarker analysis of Part B of the Ph 1b TATTON study

Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer

Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)

Abstract CT024: Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)

Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC)

Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations

A new Ornithoctona (Diptera: Hippoboscidae) species from Baikal State Nature Reserve (Russia)

Suchergebnisse filtern